Chemomab Completes Merger with Anchiano Therapeutics
USA - English
Combined company will focus on advancing Chemomab s CM-101 currently in Phase 2 for rare fibrotic indications
Company to receive gross proceeds of $45.5 Million from a PIPE financing, led by healthcare-focused investors Cormorant Asset Management, OrbiMed, Peter Thiel and Christian Angermayer s Presight Capital and Apeiron Investment Group
News provided by
Share this article
Share this article
TEL-AVIV, Israel, March. 16, 2021 /PRNewswire/ Chemomab Ltd., a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced the completion of its merger with Anchiano Therapeutics Ltd. ( Anchiano ).